Will transcatheter valve-in-valve become the standard for replacing the degenerative aortic valve bioprosthesis? Hold your horses, the jury is still out.

Abstract

From the Division of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, Ga. Disclosures: V.H.T. serves on an advisory board for St JudeMedical, Edwards Lifesciences, Boston Scientific, and Abbott Medical. V.H.T. performs research for Medtronic, Edwards Lifesciences, St Jude, Directflow, and Sorin Medical. All other authors have nothing additional to disclose with regard to commercial support. Received for publication Aug 28, 2015; accepted for publication Aug 29, 2015; available ahead of print Sept 28, 2015. Address for reprints: Vinod H. Thourani, MD, Emory University Hospital Midtown, 550 Peachtree St, NE, 6th Floor, Medical Office Tower, Atlanta, GA 30308 (E-mail: vthoura@emory.edu). J Thorac Cardiovasc Surg 2015;150:1568-9 0022-5223/$36.00 Copyright 2015 by The American Association for Thoracic Surgery http://dx.doi.org/10.1016/j.jtcvs.2015.08.114

DOI: 10.1016/j.jtcvs.2015.08.114

Cite this paper

@article{Forcillo2015WillTV, title={Will transcatheter valve-in-valve become the standard for replacing the degenerative aortic valve bioprosthesis? Hold your horses, the jury is still out.}, author={Jessica Forcillo and Lillian L Tsai and Vinod H . Thourani}, journal={The Journal of thoracic and cardiovascular surgery}, year={2015}, volume={150 6}, pages={1568-9} }